Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of VX-659 + tezacaftor + ivacaftor in cystic fibrosis patients with F508del/minimal function genotype
MOH_2018-04-09_002178Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) comparing Triple combination: VX-659 + tezacaftor + ivacaftor with Triple placebo (2 arms). Started Apr 2018; status: completed.
02
Drugs
bamocaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on MOH_2018-04-09_002178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-04-09_002178.